Literature DB >> 10405524

Differential induction of the androgen receptor transcriptional activity by selective androgen receptor coactivators.

S Yeh1, H C Chang, H Miyamoto, H Takatera, M Rahman, H Y Kang, T H Thin, H K Lin, C Chang.   

Abstract

Several new androgen receptor (AR) cofactors, associated to the ligand binding domain of AR, have been identified by our group and named AR associated protein (ARA)70, ARA55, and ARA54. Our previous reports have suggested that the cofactor ARA70 can confer the androgenic effect from 17 beta-estradiol (E2) and antiandrogen to AR. It is of interest for us to compare and determine if the specificity of sex hormones and antiandrogens could be modulated by different coactivators. Our results indicate that ARA70 is the best coactivator to confer the androgenic activity on E2. Only ARA70 and ARA55 could increase significantly the androgenic activity of hydroxyflutamide, a widely used antiandrogen for the treatment of prostate cancer. Furthermore, as compared to the relative specificity of these coactivators to AR in the prostate cancer DU145 cells, our results suggest that ARA70 has a relatively higher specificity. Together, our data suggest that the specificity of sex hormones and antiandrogens can be modulated by some selective AR coactivators. These findings may not only help us to better understand the specificity of the sex hormones and antiandrogens, but also to facilitate the development of better antiandrogens or androgens to fight the androgen-related diseases, such as prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10405524     DOI: 10.2302/kjm.48.87

Source DB:  PubMed          Journal:  Keio J Med        ISSN: 0022-9717


  12 in total

1.  From transforming growth factor-beta signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells.

Authors:  H Y Kang; H K Lin; Y C Hu; S Yeh; K E Huang; C Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

Review 2.  Minireview: modulation of hormone receptor signaling by dietary anticancer indoles.

Authors:  Gary L Firestone; Shyam N Sundar
Journal:  Mol Endocrinol       Date:  2009-10-16

Review 3.  Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis.

Authors:  Wen-Lung Ma; Hsueh-Chou Lai; Shuyuan Yeh; Xiujun Cai; Chawnshang Chang
Journal:  Endocr Relat Cancer       Date:  2014-05-06       Impact factor: 5.678

4.  HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer.

Authors:  Junkui Ai; Yujuan Wang; Javid A Dar; June Liu; Lingqi Liu; Joel B Nelson; Zhou Wang
Journal:  Mol Endocrinol       Date:  2009-10-23

Review 5.  Oncogenic activation of androgen receptor.

Authors:  Hsing-Jien Kung; Christopher P Evans
Journal:  Urol Oncol       Date:  2009 Jan-Feb       Impact factor: 3.498

Review 6.  The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy.

Authors:  Michael V Fiandalo; Wenjie Wu; James L Mohler
Journal:  Curr Drug Targets       Date:  2013-04       Impact factor: 3.465

Review 7.  Androgen-independent prostate cancer: potential role of androgen and ErbB receptor signal transduction crosstalk.

Authors:  Soha Salama El Sheikh; Jan Domin; Paul Abel; Gordon Stamp; El-Nasir Lalani
Journal:  Neoplasia       Date:  2003 Mar-Apr       Impact factor: 5.715

8.  Steroid receptor coactivator-1 (SRC-1) mediates the development of sex-specific brain morphology and behavior.

Authors:  A P Auger; M J Tetel; M M McCarthy
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

9.  Repression of androgen receptor transcription through the E2F1/DNMT1 axis.

Authors:  Conrad David Valdez; Joanne N Davis; Hana M Odeh; Tristan L Layfield; Craig S Cousineau; Thomas R Berton; David G Johnson; Kirk J Wojno; Mark L Day
Journal:  PLoS One       Date:  2011-09-26       Impact factor: 3.240

10.  Hic-5 controls BMP4 responses in prostate cancer cells through interacting with Smads 1, 5 and 8.

Authors:  D T N Shola; H Wang; R Wahdan-Alaswad; D Danielpour
Journal:  Oncogene       Date:  2011-09-26       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.